In a recent phase 1b study, the combination of a CD40 activating antibody and standard chemotherapy (gemcitabine and nab-paclitaxel) resulted in tumor shrinkage in 20 of 24 patients [98]. This evidence concerns the gene CD40 and neoplasm.